Artificial intelligence in atopic dermatitis: A narrative review

IF 11.2 1区 医学 Q1 ALLERGY
Daniel Liu BA , Benjamin D. Hu BS , Jacob Glickman MD, Ross O’Hagan MD, Helen He MD, Emma Guttman-Yassky MD, PhD
{"title":"Artificial intelligence in atopic dermatitis: A narrative review","authors":"Daniel Liu BA ,&nbsp;Benjamin D. Hu BS ,&nbsp;Jacob Glickman MD,&nbsp;Ross O’Hagan MD,&nbsp;Helen He MD,&nbsp;Emma Guttman-Yassky MD, PhD","doi":"10.1016/j.jaci.2025.06.028","DOIUrl":null,"url":null,"abstract":"<div><div>Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by substantial clinical heterogeneity, posing significant challenges to clinicians in diagnosis, severity stratification, and management. Artificial intelligence (AI) has emerged as a transformative tool in medicine and dermatology, offering innovative solutions for disease screening, severity grading, and personalized therapeutic optimization. In AD, machine learning models have been utilized to identify novel biomarkers for therapeutic development, leading to more effective, safer, and AD-specific therapies. Additionally, these models have demonstrated the ability to diagnose AD and differentiate it from other dermatologic conditions, reducing reliance on subjective clinical assessments. Future integration of AI tools into clinical practice, such as leveraging real-time transcriptomic and proteomic data to predict optimal therapeutics, monitor treatment responses, and develop AI-embedded wearable technology for remote and continuous disease monitoring, can rapidly transform AD management. However, as technology advances, ensuring bias reduction through representative training data sets and establishing proper regulatory oversight to protect patient safety and privacy will be critical for its successful and widespread adoption. As AI continues to revolutionize AD management, its integration into clinical practice holds the potential to improve diagnostic accuracy, enhance personalized treatment approaches, and bridge health care disparities, ultimately improving human health.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 4","pages":"Pages 889-898"},"PeriodicalIF":11.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674925007389","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Atopic dermatitis (AD) is a chronic, inflammatory skin condition characterized by substantial clinical heterogeneity, posing significant challenges to clinicians in diagnosis, severity stratification, and management. Artificial intelligence (AI) has emerged as a transformative tool in medicine and dermatology, offering innovative solutions for disease screening, severity grading, and personalized therapeutic optimization. In AD, machine learning models have been utilized to identify novel biomarkers for therapeutic development, leading to more effective, safer, and AD-specific therapies. Additionally, these models have demonstrated the ability to diagnose AD and differentiate it from other dermatologic conditions, reducing reliance on subjective clinical assessments. Future integration of AI tools into clinical practice, such as leveraging real-time transcriptomic and proteomic data to predict optimal therapeutics, monitor treatment responses, and develop AI-embedded wearable technology for remote and continuous disease monitoring, can rapidly transform AD management. However, as technology advances, ensuring bias reduction through representative training data sets and establishing proper regulatory oversight to protect patient safety and privacy will be critical for its successful and widespread adoption. As AI continues to revolutionize AD management, its integration into clinical practice holds the potential to improve diagnostic accuracy, enhance personalized treatment approaches, and bridge health care disparities, ultimately improving human health.
人工智能在特应性皮炎中的应用综述。
特应性皮炎(AD)是一种慢性炎症性皮肤病,其特点是具有显著的临床异质性,对临床医生在诊断、严重程度分层和管理方面提出了重大挑战。人工智能(AI)已经成为医学和皮肤病学的变革工具,为疾病筛查、严重程度分级和个性化治疗优化提供了创新的解决方案。在阿尔茨海默病中,机器学习(ML)模型已被用于识别新的生物标志物,用于治疗开发,从而导致更有效、更安全、更特异性的阿尔茨海默病治疗。此外,这些模型已经证明了诊断AD并将其与其他皮肤病区分开来的能力,减少了对主观临床评估的依赖。未来将人工智能工具整合到临床实践中,例如利用实时转录组学和蛋白质组学数据来预测最佳治疗方法,监测治疗反应,以及开发用于远程和连续疾病监测的嵌入式人工智能可穿戴技术,可以快速改变AD的管理。然而,随着技术的进步,通过具有代表性的训练数据集确保减少偏见,并建立适当的监管监督以保护患者安全和隐私,将是其成功和广泛采用的关键。随着人工智能继续革新阿尔茨海默病的管理,将其整合到临床实践中有可能提高诊断准确性,增强个性化治疗方法,弥合医疗保健差距,最终改善人类健康。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
25.90
自引率
7.70%
发文量
1302
审稿时长
38 days
期刊介绍: The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信